Literature DB >> 11220663

Hepatocellular carcinoma: susceptibility markers.

H E Blum1.   

Abstract

Genetic polymorphisms of the carcinogen-metabolizing enzymes cytochrome P450 (CYP), glutathione S-transferase (GST) M1 and N-acetyltransferase (NAT2) as well as p53 polymorphisms have been studied experimentally as susceptibility markers for hepatocellular carcinoma development in hepatocellular carcinoma cell lines and in mouse hepatocellular carcinomas. In addition, these susceptibility markers have been studied in hepatocellular carcinoma patients, in the context of coexisting alcohol consumption, smoking and/or HBV infection. To date, there is no clear evidence that susceptibility markers have an overall impact on hepatocarcinogenesis, but in subgroups of individuals, such as smokers, susceptibility markers are emerging indicators for hepatocellular carcinoma risk definition.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11220663

Source DB:  PubMed          Journal:  IARC Sci Publ        ISSN: 0300-5038


  3 in total

1.  Screening therapeutic targets of ribavirin in hepatocellular carcinoma.

Authors:  Chen Xu; Liyun Luo; Yongjun Yu; Zhao Zhang; Yi Zhang; Haimei Li; Yue Cheng; Hai Qin; Xipeng Zhang; Hongmei Ma; Yuwei Li
Journal:  Oncol Lett       Date:  2018-04-20       Impact factor: 2.967

2.  Joint effect of polymorphism in the N-acetyltransferase 2 gene and smoking on hepatocellular carcinoma.

Authors:  Jie Zhang; Feng Xu; Chunhui Ouyang
Journal:  Tumour Biol       Date:  2012-02-01

3.  Immunohistochemical markers of CYP3A4 and CYP3A7: a new tool towards personalized pharmacotherapy of hepatocellular carcinoma.

Authors:  D Fanni; M Manchia; F Lai; C Gerosa; R Ambu; G Faa
Journal:  Eur J Histochem       Date:  2016-04-11       Impact factor: 3.188

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.